Annual Report 2019
Department of Gynecology
Hiroshi Tanabe, Kouta Yokosu
Introduction
Starting from April 2018, our department’s system has changed, the number of surgeries performed has gradually increased (Table 1), and increasing numbers of patients have been registered for clinical trials and studies.
Table 1. Total number of gynecological surgeries
The Team and What We Do
A gynecologic conference is conducted biweekly and includes breast and medical oncologists and radiation oncologists. Therefore, it has been possible to register toward some clinical trials regarding malignant gynecologic oncology cases.
In particular, with regard to debulking surgery for advanced ovarian cancer and primary peritoneal cancer, we have been adopting total parietal peritonectomy in cooperation with the Colorectal Surgery Department and Hepatobiliary and Pancreatic Surgery Department. Our aim in doing so is to achieve complete surgery with no gross residual disease in a higher percentage of cases, and thereby improve prognosis. In addition, in May 2019, the Ladies Center performed the first risk-reducing salpingo-oophorectomy (RRSO) to be conducted via a system whereby people with hereditary breast and ovarian cancer syndrome (HBOC) can opt to undergo the procedure at their own expense.
Research activities
Regarding the staff, Dr. Tanabe is the principal investigator in the study “Randomized Phase III Trial of the need for adjuvant chemotherapy in stage I epithelial ovarian cancer after comprehensive staging surgery” performed by the Japanese Gynecological Oncology Group (JGOG). This specified clinical research application has been certified by the Certified Review Board (CRB) of our institution, allowing our hospital to continue with the research and patient registration.
Our department has been approved as a new observer institution of Japan Clinical Oncology Group (JCOG) this year, and is preparing to be registrable for clinicals trial of JCOG in the future.
Clinical trial
Randomized Phase III Trial of the need for adjuvant chemotherapy in stage I epithelial ovarian cancer after comprehensive staging surgery (JGOG3020)
Education
Regarding the staff, Dr. Yokosu, who is aiming to specialize in gynecologic oncology, guidance and education, is focusing on operational methods for malignant gynecologic tumors, along with clinical practice and clinical research. In addition, he is preparing to accept a position as a residential doctor.
Future prospects
Proactively registering for clinical care of gynecologic malignant tumors focusing on a global clinical trial, JCOG, and JGOG clinical trial, to be the center of research to establish new findings.
Planning a clinical study on expanded debulking surgery as total parietal peritonectomy for advanced ovarian cancer, to establish safety in invasive surgical procedures and to establish good prognosis over the long term.